Abstract:Integrin alpha(v)beta(6) is overexpressed in a variety of cancers, and its expression is often associated with poor prognosis. Therefore, there is a need to develop affinity reagents for noninvasive imaging of integrin alpha(v)beta(6) expression since it may provide early cancer diagnosis, more accurate prognosis, and better treatment planning. We recently engineered and validated highly stable cystine knot peptides that selectively bind integrin alpha(v)beta(6) with no cross-reactivity to integrins alpha(v)beta(5), alpha(5)beta(1), or alpha(v)beta(3), also known to be overexpressed in many cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging integrin alpha(v)beta(6) positive tumors. Cystine knot peptide, S(0)2, was first conjugated with a single amino acid chelate (SAAC) and labeled with [Tc-99m(H2O)(3)(CO)(3)](+). The resulting probe, Tc-99m-SAAC-S(0)2, was then evaluated by in vitro cell uptake studies using two alpha(v)beta(6) positive cell lines (human lung adenocarcinoma cell line HCC4006 and pancreatic cancer cell line BxPC-3) and two alpha(v)beta(6) negative cell lines (human lung adenocarcinoma cell line H838 and human embryonic kidney cell line 293T). Next, SPECT/CT and biodistribution studies were performed in nude mice bearing HCC4006 and H838 tumor xenografts to evaluate the in vivo performance of Tc-99m-SAAC-S(0)2. Significant differences in the uptake of Tc-99m-SAAC-S(0)2 were observed in alpha(v)beta(6) positive vs negative cells (P < 0.05). Biodistribution and small animal SPECT/CT studies revealed that Tc-99m-SAAC-S(0)2 accumulated to moderate levels in antigen positive tumors (similar to 2% ID/g at 1 and 6 h postinjection, n = 3 or 4/group). Moreover, the probe demonstrated tumor-to-background tissue ratios of 6.81 +/- 2.32 (tumor-to-muscle) and 1.63 +/- 0.18 (tumor-to-blood) at 6 h postinjection in alpha(v)beta(6) positive tumor xenografts. Co-incubation of the probe with excess amount of unlabeled S(0)2 as a blocking agent demonstrated significantly reduced tumor uptake, which is consistent with specific binding to the target. Renal filtration was the main route of clearance. In conclusion, knottin peptides are excellent scaffolds for which to develop highly stable imaging probes for a variety of oncological targets. Tc-99m-SAAC-S(0)2 demonstrates promise for use as a SPECT agent to image integrin alpha(v)beta(6) expression in living systems.

First-in-human Pilot Study of an Integrin Α6-Targeted Radiotracer for SPECT Imaging of Breast Cancer

Integrin Α6-Targeted Positron Emission Tomography Imaging of Colorectal Cancer

Integrin Α6 Targeted Near Infrared Fluorescent Imaging and Photoacoustic Imaging of Hepatocellular Carcinoma in Mice

Development and Preclinical Evaluation of a Cyclic PET Tracer Targeting Integrin-Α6 on Colorectal Cancer Models

Molecular Imaging Using PET and SPECT for Identification of Breast Cancer Subtypes

Small-animal SPECT/CT Imaging of Cancer Xenografts and Pulmonary Fibrosis Using a 99m Tc-labeled Integrin Αvβ6-Targeting Cyclic Peptide with Improved in Vivo Stability

Molecular Imaging Of Integrin Alpha(V)Beta(6) Expression In Living Subjects

Molecular Imaging of Integrin Αvβ6 Expression in Living Subjects.

Integrin Αvβ6–targeted SPECT Imaging for Pancreatic Cancer Detection

Integrin Alpha(V)Beta(6)-Targeted Spect Imaging for Pancreatic Cancer Detection

An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake

Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

99Mtc-3P-rgd2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin Αvβ3-Targeted Therapy

A Near-Infrared Phthalocyanine Dye-Labeled Agent for Integrin Alpha V Beta 6-Targeted Theranostics of Pancreatic Cancer

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

Evaluation of a 99Mtc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin Αvβ3-Positive Breast Cancer

Clinical Translation of a 68Ga-Labeled Integrin Αvβ6–targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging